Article in Nature Biotechnology about our new name and plans for the future (subscription needed to read full text).
Related news
First Treatment Approved under EAMS Developed Using MRC Technology Antibody Humanization Expertise
Read more: First Treatment Approved under EAMS Developed Using MRC Technology Antibody Humanization Expertise
LifeArc monetises Keytruda® royalty interests to fund further research and investment
Read more: LifeArc monetises Keytruda® royalty interests to fund further research and investmentBreakthrough Melanoma Treatment, Keytruda, Developed Using Antibody Humanization Expertise at UK’s MRC Technology
Read more: Breakthrough Melanoma Treatment, Keytruda, Developed Using Antibody Humanization Expertise at UK’s MRC Technology